RETRACTED ARTICLE

This article was retracted on 6 November 2026.

RETRACTED: Further evidence: Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis

Cascadia Journal of Biomedical Research
DOI: 10.58302/hwb4k534

The retraction notice, which explains why this article was retracted, is published on the article page:
http://localhost:3110/publication/89

The pages that follow reproduce this version of the article, marked as retracted on every page. Its findings and conclusions should not be relied upon.

RETRACTED ON 6 November 2026

Further evidence: Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real?World Analysis

Dmitri Dvo?ák, Kenji Zhang, Sofia Silva, Joon-ho Hayashi, Henrik Hansen, Omar Abdi, Giulia Marchetti, Vikram Sharma, Kenji Kim, Viktor Dvo?ák, Mei Watanabe, Anton Jovanovi?, Dagny Larsen, Léa Delacroix, Omar Hakimi, Dagny Bergström, Hannah Engel, Rosa Santoro, Tunde Okonkwo, Margot Lemaire, Stefan Sandberg, Margot Moreau, Henrik Lindgren, Marcus Holmberg, Adaeze Tembo, Rania Abdi, Idris Khalil, Clara Müller, Nikhil Iyer, Dagny Lindgren, Inês Castellanos

Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non?cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.??To assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS).

This is the demonstration PDF of the article.

RETRACTED

RETRACTED ON 6 November 2026

Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non?cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.??To assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS).

This is the demonstration PDF of the article.

RETRACTED

RETRACTED ON 6 November 2026

Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non?cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.??To assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS).

This is the demonstration PDF of the article.

RETRACTED